RNAZ PE Ratio & Valuation, Is RNAZ Overvalued

Historical Valuation

Transcode Therapeutics Inc (RNAZ) is now in the Fair zone, suggesting that its current forward PS ratio of 54.28 is considered Fairly compared with the five-year average of -2.09. The fair price of Transcode Therapeutics Inc (RNAZ) is between 5.78 to 11.81 according to relative valuation method.

Relative Value

Fair Zone

5.78-11.81

Current Price：9.31

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Transcode Therapeutics Inc (RNAZ) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Transcode Therapeutics Inc (RNAZ) has a current Price-to-Book (P/B) ratio of 4.33. Compared to its 3-year average P/B ratio of 0.11, the current P/B ratio is approximately 3843.04% higher. Relative to its 5-year average P/B ratio of 0.58, the current P/B ratio is about 648.75% higher. Transcode Therapeutics Inc (RNAZ) has a Forward Free Cash Flow (FCF) yield of approximately -214.00%. Compared to its 3-year average FCF yield of -553.96%, the current FCF yield is approximately -61.37% lower. Relative to its 5-year average FCF yield of -370.60%, the current FCF yield is about -42.26% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RNAZ competitors is 10.86, providing a benchmark for relative valuation. Transcode Therapeutics Inc Corp (RNAZ.O) exhibits a P/S ratio of 54.28, which is 400% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RNAZ increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RNAZ in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RNAZ currently overvalued or undervalued?

What is Transcode Therapeutics Inc (RNAZ) fair value?

RNAZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Transcode Therapeutics Inc (RNAZ) is between 5.78 to 11.81 according to relative valuation method.

How does RNAZ's valuation metrics compare to the industry average?

The average P/S ratio for RNAZ's competitors is 10.86, providing a benchmark for relative valuation. Transcode Therapeutics Inc Corp (RNAZ) exhibits a P/S ratio of 54.28, which is 400.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Transcode Therapeutics Inc (RNAZ) as of Mar 20 2026?

As of Mar 20 2026, Transcode Therapeutics Inc (RNAZ) has a P/B ratio of 4.33. This indicates that the market values RNAZ at 4.33 times its book value.

What is the current FCF Yield for Transcode Therapeutics Inc (RNAZ) as of Mar 20 2026?

As of Mar 20 2026, Transcode Therapeutics Inc (RNAZ) has a FCF Yield of -214.00%. This means that for every dollar of Transcode Therapeutics Inc's market capitalization, the company generates -214.00 cents in free cash flow.

What is the current Forward P/E ratio for Transcode Therapeutics Inc (RNAZ) as of Mar 20 2026?

As of Mar 20 2026, Transcode Therapeutics Inc (RNAZ) has a Forward P/E ratio of -5.68. This means the market is willing to pay $-5.68 for every dollar of Transcode Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Transcode Therapeutics Inc (RNAZ) as of Mar 20 2026?

As of Mar 20 2026, Transcode Therapeutics Inc (RNAZ) has a Forward P/S ratio of 54.28. This means the market is valuing RNAZ at $54.28 for every dollar of expected revenue over the next 12 months.

RNAZ Valuation